Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	hr+/her2- metastatic breast cancer cdk4/6 combined endocrine therapy with cdk4/6 inhibitors hormone resistance eribulin eribulin chemotherapy efficacy eribulin chemotherapy safety visceral metastases lung metastases Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/714a7172db8b443795259379d343327b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Ejemplares similares